Claims for Patent: 5,817,911

Summary for Patent: 5,817,911

Title:	Transgenic mice expressing alveolar MCP-1
Abstract:	A transgenic, non-human animal is provided which overexpresses a gene responsible for the accumulation of monocytes and leukocytes. The animal is preferably a mammal and more preferably a mouse, rat or guinea pig. The transgenic animal is created by artificially inserting a transgene into a fertilized egg of the animal which egg is then inserted within a pseudo pregnant female where it is allowed to grow. The transgene preferably expresses human Monocyte Chemoattractant Protein-1 (MCP-1) and more preferably overexpresses MCP-1 in type II pulmonary epithelial cells. The invention includes DNA constructs and vectors containing the constructs with a particularly preferred vector being SPC-MCP-1. The plasmid SPC-MCP-1 includes a promoter operatively linked to a human MCP-1 coding sequence. The transgenic animal provides a useful animal model for testing drugs for their efficacy with respect to the treatment of diseases and conditions which result in an acceptable high accumulation of monocytes and/or lymphocytes.
Inventor(s):	Williams; Lewis T. (Tiburon, CA), Gunn; Michael Dee (San Francisco, CA)
Assignee:	Regents of the University of California (Alameda, CA)
Application Number:	08/420,001
Patent Claims:	1. A transgenic mouse whose somatic and germ cells comprise a transgene: said transgene comprising a sequence encoding a mammalian monocyte chemoattractantprotein (MCP-1) operably linked to a surfactant protein C promoter, and at least one intron, wherein said transgene is expressed in the cells of the lung of said mouse and provides for an abnormally high level of accumulation of blood mononuclear leukocytes at the site of expression. 2. The transgenic mouse of claim 1, wherein the level of accumulation is ten times or more than the level of accumulation in the absence of the transgene. 3. The transgenic mouse of claim 1, wherein the transgene encodes human Monocyte Chemoattractant Protein-1 (hMCP-1). 4. The transgenic mouse of claim 1, wherein said lung cells are type II alveolar cells and bronchoalveolar epithelial cells. 5. A method of assaying a drug with respect to its ability to decrease the accumulation of blood cells associated with the inflammatory process, comprising: administering the drug to a transgenic mouse whose somatic and germ cells comprises a transgene: said transgene comprising sequence encoding a mammalian monocyte chemoattractantprotein (MCP-1) operably linked to a surfactant protein C promoter, and at least one intron, wherein said transgene is expressed in the cells of the lung of said mouse and provides for an abnormally high level of accumulation of blood mononuclear leukocytes at the site of expression; and determining the effect of the drug on the level of blood cell accumulation. 6. The method of claim 5, wherein the determining comprises collecting said accumulated cells and determining if the drug decreases the number of accumulated cells relative to a standard wherein the drug is not administered, wherein the transgene encodes human Monocyte Chemoattractant Protein-1 (hMCP-1).

Details for Patent 5,817,911

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26